GlassScriptPhysician profile
Lisa Fox
NPI 1427027648
$25,864.36
in general payments reported to CMS, 2019-2025
13 companies · $2,447 in 2025
The $2,447 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,202 · 2022: $4,541 · 2023: $11K · 2024: $3,708 · 2025: $2,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $2,285 · Honoraria: $2,160 · Travel and Lodging: $640 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,952.50 |
| Food and Beverage | $2,285.32 |
| Honoraria | $2,160.00 |
| Travel and Lodging | $639.52 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $8,071.17 | 2023-2024 | Evobrutinib, Mavenclad |
| Genentech USA, INC. | $6,519.08 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Genentech, INC. | $4,606.74 | 2022-2024 | |
| Horizon Therapeutics Plc | $2,878.16 | 2021-2023 | Uplizna |
| Tg Therapeutics, INC. | $1,824.96 | 2024 | |
| Genzyme Corporation | $793.98 | 2021-2024 | |
| Novartis Pharma Ag | $710.50 | 2021 | |
| Amgen INC. | $249.43 | 2024-2025 | Uplizna |
| Janssen Biotech, INC. | $83.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $38.75 | 2021-2023 | |
| Biogen, INC. | $36.56 | 2023 | |
| Neurocrine Biosciences, INC. | $27.90 | 2025 | |
| Celgene Corporation | $23.14 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.